Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

De Novo Designed Amphipathic α-Helical Antimicrobial Peptides Incorporating Dab and Dap Residues on the Polar Face To Treat the Gram-Negative Pathogen, Acinetobacter baumannii.

Mant CT, Jiang Z, Gera L, Davis T, Nelson KL, Bevers S, Hodges RS.

J Med Chem. 2019 Apr 11;62(7):3354-3366. doi: 10.1021/acs.jmedchem.8b01785. Epub 2019 Mar 21.

PMID:
30848594
2.

Small molecule BKM1972 inhibits human prostate cancer growth and overcomes docetaxel resistance in intraosseous models.

Chen Y, Gera L, Zhang S, Li X, Yang Y, Mamouni K, Wu AY, Liu H, Kucuk O, Wu D.

Cancer Lett. 2019 Apr 1;446:62-72. doi: 10.1016/j.canlet.2019.01.010. Epub 2019 Jan 18.

PMID:
30660650
3.

Bifunctional ligands of the bradykinin B2 and B1 receptors: An exercise in peptide hormone plasticity.

Marceau F, Bawolak MT, Fortin JP, Morissette G, Roy C, Bachelard H, Gera L, Charest-Morin X.

Peptides. 2018 Jul;105:37-50. doi: 10.1016/j.peptides.2018.05.007. Epub 2018 May 23. Review.

PMID:
29802875
4.

Sensitive liquid chromatography/tandem mass spectrometry method for the determination of two novel highly lipophilic anticancer drug candidates in rat plasma and tissues.

Hooshfar S, Linzey MR, Wu D, Gera L, Mamouni K, Li X, Chen Y, Yang Y, Olorunyolemi O, Bartlett MG.

Biomed Chromatogr. 2018 Feb;32(2). doi: 10.1002/bmc.4064. Epub 2017 Sep 12.

5.
6.

Inhibition of skeletal growth of human prostate cancer by the combination of docetaxel and BKM1644: an aminobisphosphonate derivative.

Zhang S, Gera L, Mamouni K, Li X, Chen Z, Kucuk O, Wu D.

Oncotarget. 2016 May 10;7(19):27489-98. doi: 10.18632/oncotarget.8481.

7.

Modulation of Kinin B2 Receptor Signaling Controls Aortic Dilatation and Rupture in the Angiotensin II-Infused Apolipoprotein E-Deficient Mouse.

Moran CS, Rush CM, Dougan T, Jose RJ, Biros E, Norman PE, Gera L, Golledge J.

Arterioscler Thromb Vasc Biol. 2016 May;36(5):898-907. doi: 10.1161/ATVBAHA.115.306945. Epub 2016 Mar 10.

PMID:
26966276
8.

Platform technology to generate broadly cross-reactive antibodies to α-helical epitopes in hemagglutinin proteins from influenza A viruses.

Jiang Z, Gera L, Mant CT, Hirsch B, Yan Z, Shortt JA, Pollock DD, Qian Z, Holmes KV, Hodges RS.

Biopolymers. 2016 Mar;106(2):144-159. doi: 10.1002/bip.22808.

PMID:
26799790
9.

In Vivo Effects of Bradykinin B2 Receptor Agonists with Varying Susceptibility to Peptidases.

Jean M, Gera L, Charest-Morin X, Marceau F, Bachelard H.

Front Pharmacol. 2016 Jan 12;6:306. doi: 10.3389/fphar.2015.00306. eCollection 2015.

10.

Bradykinin antagonists and thiazolidinone derivatives as new potential anti-cancer compounds.

Avdieiev S, Gera L, Havrylyuk D, Hodges RS, Lesyk R, Ribrag V, Vassetzky Y, Kavsan V.

Bioorg Med Chem. 2014 Aug 1;22(15):3815-23. doi: 10.1016/j.bmc.2014.06.046. Epub 2014 Jun 30.

PMID:
25012567
11.

Vasopeptidase-activated latent ligands of the histamine receptor-1.

Gera L, Roy C, Charest-Morin X, Marceau F.

Int Immunopharmacol. 2013 Nov;17(3):677-83. doi: 10.1016/j.intimp.2013.08.014. Epub 2013 Sep 7.

12.

Blocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension.

Tian W, Jiang X, Tamosiuniene R, Sung YK, Qian J, Dhillon G, Gera L, Farkas L, Rabinovitch M, Zamanian RT, Inayathullah M, Fridlib M, Rajadas J, Peters-Golden M, Voelkel NF, Nicolls MR.

Sci Transl Med. 2013 Aug 28;5(200):200ra117. doi: 10.1126/scitranslmed.3006674.

13.

Inhibitory effects of cytoskeleton disrupting drugs and GDP-locked Rab mutants on bradykinin B₂ receptor cycling.

Charest-Morin X, Fortin S, Lodge R, Roy C, Gera L, Gaudreault RC, Marceau F.

Pharmacol Res. 2013 May;71:44-52. doi: 10.1016/j.phrs.2013.02.007. Epub 2013 Feb 27.

14.

Bifunctional epitope-agonist ligands of the bradykinin B(2) receptor.

Gera L, Roy C, Marceau F.

Biol Chem. 2013 Mar;394(3):379-83. doi: 10.1515/hsz-2012-0286.

15.

Discovery and therapeutic potential of kinin receptor antagonists.

Whalley ET, Figueroa CD, Gera L, Bhoola KD.

Expert Opin Drug Discov. 2012 Dec;7(12):1129-48. doi: 10.1517/17460441.2012.729038. Epub 2012 Oct 25. Review.

PMID:
23095011
16.
17.

Prolonged signalling and trafficking of the bradykinin B2 receptor stimulated with the amphibian peptide maximakinin: insight into the endosomal inactivation of kinins.

Bawolak MT, Roy C, Gera L, Marceau F.

Pharmacol Res. 2012 Feb;65(2):247-53. doi: 10.1016/j.phrs.2011.11.004. Epub 2011 Nov 16.

18.

An in vitro reconstitution system to address the mechanism of the vascular expression of the bradykinin B₁ receptor in response to angiotensin converting enzyme inhibition.

Roy C, Marceau E, Gera L, Marceau F.

Vascul Pharmacol. 2012 Aug 19;57(1):15-23. doi: 10.1016/j.vph.2011.09.003. Epub 2011 Oct 2.

19.

Regulatory T cells limit vascular endothelial injury and prevent pulmonary hypertension.

Tamosiuniene R, Tian W, Dhillon G, Wang L, Sung YK, Gera L, Patterson AJ, Agrawal R, Rabinovitch M, Ambler K, Long CS, Voelkel NF, Nicolls MR.

Circ Res. 2011 Sep 30;109(8):867-79. doi: 10.1161/CIRCRESAHA.110.236927. Epub 2011 Aug 25.

20.

Met-Lys-bradykinin-Ser-Ser, a peptide produced by the neutrophil from kininogen, is metabolically activated by angiotensin converting enzyme in vascular tissue.

Gera L, Roy C, Bawolak MT, Bouthillier J, Adam A, Marceau F.

Pharmacol Res. 2011 Nov;64(5):528-34. doi: 10.1016/j.phrs.2011.08.001. Epub 2011 Aug 11.

21.

Stereoselective determination of the epimer mixtures of itraconazole in human blood plasma using HPLC and fluorescence detection.

Pyrgaki C, Bannister SJ, Gera L, Gerber JG, Gal J.

Chirality. 2011 Aug;23(7):495-503. doi: 10.1002/chir.20932. Epub 2011 Jun 10.

PMID:
21671287
23.

Design of fluorescent bradykinin analogs: application to imaging of B2 receptor-mediated agonist endocytosis and trafficking and angiotensin-converting enzyme.

Gera L, Bawolak MT, Roy C, Lodge R, Marceau F.

J Pharmacol Exp Ther. 2011 Apr;337(1):33-41. doi: 10.1124/jpet.110.177147. Epub 2011 Jan 4.

PMID:
21205920
24.

Strong cytotoxic effect of the bradykinin antagonist BKM-570 in ovarian cancer cells--analysis of the molecular mechanisms of its antiproliferative action.

Jutras S, Bachvarova M, Keita M, Bascands JL, Mes-Masson AM, Stewart JM, Gera L, Bachvarov D.

FEBS J. 2010 Dec;277(24):5146-60. doi: 10.1111/j.1742-4658.2010.07928.x. Epub 2010 Nov 16. Erratum in: FEBS J. 2011 Apr;278(6):999. Gera, Lajos [added].

25.

Vascular smooth muscle contractility assays for inflammatory and immunological mediators.

Marceau F, deBlois D, Petitclerc E, Levesque L, Drapeau G, Audet R, Godin D, Larrivée JF, Houle S, Sabourin T, Fortin JP, Morissette G, Gera L, Bawolak MT, Koumbadinga GA, Bouthillier J.

Int Immunopharmacol. 2010 Nov;10(11):1344-53. doi: 10.1016/j.intimp.2010.08.016. Epub 2010 Sep 8. Review.

26.

A ligand-based approach to investigate the expression and function of angiotensin converting enzyme in intact human umbilical vein endothelial cells.

Koumbadinga GA, Bawolak MT, Marceau E, Adam A, Gera L, Marceau F.

Peptides. 2010 Aug;31(8):1546-54. doi: 10.1016/j.peptides.2010.04.027. Epub 2010 May 7.

27.

Effects of inactivation-resistant agonists on the signalling, desensitization and down-regulation of bradykinin B(2) receptors.

Bawolak MT, Fortin S, Bouthillier J, Adam A, Gera L, C-Gaudreault R, Marceau F.

Br J Pharmacol. 2009 Nov;158(5):1375-86. doi: 10.1111/j.1476-5381.2009.00409.x. Epub 2009 Sep 28.

28.

N-(Fluorenyl-9-methoxycarbonyl)amino acid amide derivatives as a new class of anti-cancer agents.

Gera L, Chan DC, Simkeviciene V, Bunn PA Jr, Stewart JM.

Adv Exp Med Biol. 2009;611:465-6. No abstract available.

PMID:
19400267
29.

Fluorescent ligands of the bradykinin B1 receptors: pharmacologic characterization and application to the study of agonist-induced receptor translocation and cell surface receptor expression.

Bawolak MT, Gera L, Morissette G, Bouthillier J, Stewart JM, Gobeil LA, Lodge R, Adam A, Marceau F.

J Pharmacol Exp Ther. 2009 Apr;329(1):159-68. doi: 10.1124/jpet.108.149724. Epub 2009 Jan 9.

PMID:
19136639
30.

BKM1740, an acyl-tyrosine bisphosphonate amide derivative, inhibits the bone metastatic growth of human prostate cancer cells by inducing apoptosis.

Seo SI, Gera L, Zhau HE, Qian WP, Iqbal S, Johnson NA, Zhang S, Zayzafoon M, Stewart J, Wang R, Chung LW, Wu D.

Clin Cancer Res. 2008 Oct 1;14(19):6198-206. doi: 10.1158/1078-0432.CCR-08-1023.

31.

Computational discovery of novel low micromolar human pregnane X receptor antagonists.

Ekins S, Kholodovych V, Ai N, Sinz M, Gal J, Gera L, Welsh WJ, Bachmann K, Mani S.

Mol Pharmacol. 2008 Sep;74(3):662-72. doi: 10.1124/mol.108.049437. Epub 2008 Jun 25.

PMID:
18579710
32.

A fluorescent version of the bradykinin B2 receptor antagonist B-9430: pharmacological characterization and use in live cell imaging.

Bawolak MT, Gera L, Bouthillier J, Stewart JM, Adam A, Marceau F.

Peptides. 2008 Sep;29(9):1626-30. doi: 10.1016/j.peptides.2008.05.007. Epub 2008 May 17.

PMID:
18565624
33.

Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells.

Yemelyanov A, Czwornog J, Gera L, Joshi S, Chatterton RT Jr, Budunova I.

Cancer Res. 2008 Jun 15;68(12):4763-73. doi: 10.1158/0008-5472.CAN-07-6104.

34.

Structural modification of the highly potent peptide bradykinin B1 receptor antagonist B9958.

Gera L, Stewart JM, Fortin JP, Morissette G, Marceau F.

Int Immunopharmacol. 2008 Feb;8(2):289-92. doi: 10.1016/j.intimp.2007.06.006. Epub 2007 Jul 5.

PMID:
18182242
36.

[Effects of phosphatidylcholine therapy after hindlimb ischemia and reperfusion].

Varga R, Gera L, Török L, Kaszaki J, Szabó A, Nagy K, Boros M.

Magy Seb. 2006 Dec;59(6):429-36. Hungarian.

PMID:
17432083
37.

Beneficial effects of phosphatidylcholine during hindlimb reperfusion.

Gera L, Varga R, Török L, Kaszaki J, Szabó A, Nagy K, Boros M.

J Surg Res. 2007 May 1;139(1):45-50. Epub 2007 Feb 1.

PMID:
17275842
38.
39.

A nonpeptide antagonist reveals a highly glycosylated state of the rabbit kinin B1 receptor.

Fortin JP, Dziadulewicz EK, Gera L, Marceau F.

Mol Pharmacol. 2006 Apr;69(4):1146-57. Epub 2006 Jan 11.

PMID:
16407468
40.

Discovery of a dual-function peptide that combines aminopeptidase N inhibition and kinin B1 receptor antagonism.

Gera L, Fortin JP, Adam A, Stewart JM, Marceau F.

J Pharmacol Exp Ther. 2006 Apr;317(1):300-8. Epub 2005 Dec 20.

PMID:
16368899
41.

[Early clinical experience with postoperative monitoring of a patient after laparoscopic splenectomy combined with spleen autotransplantation. A case report].

Svébis M, Pap-Szekeres J, Venczel L, Gera L, Rajtár M, Sinkó M, Furka I, Mikó I.

Magy Seb. 2005 Apr;58(2):80-3. Hungarian.

PMID:
16018272
42.

Endogenous aminopeptidase N decreases the potency of peptide agonists and antagonists of the kinin B1 receptors in the rabbit aorta.

Fortin JP, Gera L, Bouthillier J, Stewart JM, Adam A, Marceau F.

J Pharmacol Exp Ther. 2005 Sep;314(3):1169-76. Epub 2005 May 26.

PMID:
15919764
43.

Combination cancer chemotherapy with one compound: pluripotent bradykinin antagonists.

Stewart JM, Gera L, Chan DC, York EJ, Simkeviciene V, Bunn PA Jr, Taraseviciene-Stewart L.

Peptides. 2005 Aug;26(8):1288-91.

PMID:
15878795
44.

Treatment of severe pulmonary hypertension: a bradykinin receptor 2 agonist B9972 causes reduction of pulmonary artery pressure and right ventricular hypertrophy.

Taraseviciene-Stewart L, Scerbavicius R, Stewart JM, Gera L, Demura Y, Cool C, Kasper M, Voelkel NF.

Peptides. 2005 Aug;26(8):1292-300.

PMID:
15878794
45.

Characterization of the B2 receptor and activity of bradykinin analogs in SHP-77 cell line by Cytosensor microphysiometer.

Bironaite D, Gera L, Stewart JM.

Chem Biol Interact. 2004 Dec 7;150(3):283-93.

PMID:
15560894
46.

New lung cancer drugs from bradykinin antagonists.

Stewart JM, Gera L, Chan DC, York EJ, Stewart LT, Simkeviciene V, Helfrich B.

Chest. 2004 May;125(5 Suppl):148S. No abstract available.

PMID:
15136471
47.

Evidence for bradykinin as a stimulator of thirst.

Cadnapaphornchai MA, Rogachev B, Summer SN, Chen YC, Gera L, Stewart JM, Schrier RW.

Am J Physiol Renal Physiol. 2004 May;286(5):F875-80. Epub 2004 Jan 6.

48.

The bradykinin B1 receptor contributes to the cardioprotective effects of AT1 blockade after experimental myocardial infarction.

Tschöpe C, Spillmann F, Altmann C, Koch M, Westermann D, Dhayat N, Dhayat S, Bascands JL, Gera L, Hoffmann S, Schultheiss HP, Walther T.

Cardiovasc Res. 2004 Feb 15;61(3):559-69.

PMID:
14962486
49.

Changes in amino-terminal portion of human B2 receptor selectively increase efficacy of synthetic ligand HOE 140 but not of cognate ligand bradykinin.

Schroeder C, Breit A, Böning H, Dedio J, Gera L, Stewart J, Müller-Esterl W.

Am J Physiol Heart Circ Physiol. 2003 Jun;284(6):H1924-32. Epub 2003 Feb 6.

50.

Methylprednisolone causes matrix metalloproteinase-dependent emphysema in adult rats.

Choe KH, Taraseviciene-Stewart L, Scerbavicius R, Gera L, Tuder RM, Voelkel NF.

Am J Respir Crit Care Med. 2003 Jun 1;167(11):1516-21. Epub 2003 Jan 9.

PMID:
12522028

Supplemental Content

Support Center